Text Size

Vitamin D, Diet and Activity Study (ViDA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01240213
First received: November 9, 2010
Last updated: August 16, 2012
Last verified: August 2012
History of Changes
  Purpose

Experimental and human data suggests that vitamin D could protect against breast cancer. Overweight/obese individuals are at increased risk of low vitamin D levels. Vitamin D may reduce production of fat tissue, thereby reducing weight gain, which would result in lower levels of adipose-derived hormones and other breast cancer risk factors.The purpose of this study is to test the effect of vitamin D supplementation on the response to a weight loss (diet + exercise) intervention and select breast cancer risk factors in overweight and obese postmenopausal women with low blood vitamin D levels.


Condition Intervention
Breast Cancer
Obesity
Hypovitaminosis D
 Dietary Supplement: Vitamin D
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: Vitamin D, Weight Loss, and Breast Cancer Biomarkers

Resource links provided by NLM:

Drug Information available for: Vitamin D
U.S. FDA Resources

Further study details as provided by Fred Hutchinson Cancer Research Center:

Primary Outcome Measures:
  • Compare the effects of a 1-year one year Vitamin D supplementation vs placebo, on weight loss in postmenopausal women following a weight loss diet and exercise program. [ Time Frame: One Year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers (insulin,glucose,CRP) associated with increased breast cancer risk. [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and bench press in women undergoing weight loss. [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Test the effect of 12-month vitamin D supplementation on effects on quality of life (QOL) in women undergoing weight loss. [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Effect of Vitamin D supplementation on breast epithelial cell cytomorphology [ Time Frame: One Year ] [ Designated as safety issue: No ]
    In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology index) obtained through random periareolar fine needle aspiration (RPFNA).

  • Effect of Vitamin D on epithelial cell gene expression [ Time Frame: One year ] [ Designated as safety issue: No ]
    In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell gene expression as measured by qRT-PCR. The breast epithelial cells are collected by RPFNA


Enrollment: 218
Study Start Date: October 2010
Estimated Study Completion Date: September 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Vitamin D
2000 IU per day of Vitamin D
 Dietary Supplement: Vitamin D
2000 IU per day of Vitamin D
Other Name: calciferol
Placebo Comparator: Placebo Dietary Supplement: Placebo
1 Placebo per day
Other Name: Sugar pill

Detailed Description:

Objective: To test the incremental effect of vitamin D supplementation (2000 IU/day) in 228 overweight and obese postmenopausal women with low blood vitamin D levels on response to a weight loss (diet + exercise) intervention in a double-blind placebo-controlled clinical trial.

Primary Aim:

• Determine the effects of 12-months vitamin D supplementation vs. placebo on weight loss in women following a weight loss diet and exercise program.

Secondary Aims:

  • Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers associated with increased breast cancer risk (insulin, glucose, CRP).
  • Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and bench press in women undergoing weight loss.
  • Test the effect of 12-month vitamin D supplementation on effects on quality of life (QOL) in women undergoing weight loss.

Additional Aims:

  • In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology index) obtained through random periareolar fine needle aspiration (RPFNA).
  • Collect subcutaneous abdominal fat aspirations in the 50% subsample of women.

OUTLINE: This is a randomized study. Participants are stratified according to body mass index (< 30 vs ≥ 30) and RPFNA-consent. All participants will receive a 6-month weight loss intervention (prescribed weight loss goal of 10% of initial body weight) followed by 6 months' maintenance therapy.

Baseline, 6-, and 12-month measurements will include weight, BMI, waist and hip circumference, serum 25-hydroxyvitamin D, fasting blood samples, and questionnaires on details of diet especially items containing vitamin D, physical activity levels, sun exposure including clothing and sunscreen habits, dietary supplement and vitamin use, and medications.

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 50-75 years
  • Postmenopausal (no periods for past 12 months)
  • Screening serum vitamin D (25(OH)D) between 10 and 32 ng/mL ("insufficient")
  • No menopausal HRT use of any type including vaginal X 6 months and willing to avoid use for study duration
  • BMI > 25.0 kg/m2 (> 23.0 for Asians)
  • Physically able to undertake a calorie reduction and exercise program
  • Able to come for clinic visits, classes, and measurements, fill out questionnaires and logs in English
  • Gives informed consent, agrees to be randomly assigned

Exclusion Criteria:

  • Currently using more that 400 IU vitamin D from supplemental sources
  • Screening vitamin D level < 10 ng/mL (will be referred to primary provider) or > 32 ng/mL (already sufficient)
  • Osteoporosis
  • Renal disease, history of kidney stones
  • Any contra-indications to taking vitamin D 2000 IU/day
  • Plans to leave the study area within the follow-up period
  • Plans to join another organized weight loss program or take appetite suppressant medication during the study period
  • History of bariatric surgery
  • Current use of medications likely to interfere with adherence to interventions or study outcomes
  • Current smoker
  • Personal history of invasive or in situ breast cancer
  • Personal history of invasive cancer other than breast: except for non- melanoma skin cancer which would be eligible
  • Diabetes mellitus
  • Abnormalities on screening physical that contraindicate participation
  • Severe congestive heart failure per NYHA criteria 3 & 4
  • Contraindications for entry into a research exercise program: recent (within 6 months) myocardial infarction, pulmonary edema, myocarditis, pericarditis, unstable angina, pulmonary embolism, deep vein thrombosis, uncontrolled hypertension (systolic > 200, diastolic > 100), orthostatic hypotension, moderate/severe aortic stenosis, uncontrolled arrythmia, uncontrolled congestive heart failure, left bundle branch block, history of cardiac arrest or stroke
  • Alcohol or drug abuse, significant mental illness (as assessed by study staff impression)
  • For the RPFNA/adipose tissue substudy: bilateral breast cancer, bilateral mastectomy, unable or unwilling to stop aspirin or NSAIDs for 1 week before and after the procedure, allergy to anesthetics or local anesthetics.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01240213

Locations
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Investigators
Principal Investigator: Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center
  More Information

No publications provided

Responsible Party: Anne McTiernan, MD PhD, FHCRC
ClinicalTrials.gov Identifier: NCT01240213     History of Changes
Other Study ID Numbers: SAC110024, IR 7297
Study First Received: November 9, 2010
Last Updated: August 16, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Fred Hutchinson Cancer Research Center:
Vitamin D
lifestyle intervention
postmenopausal women

Additional relevant MeSH terms:
Breast Neoplasms
Obesity
Rickets
Avitaminosis
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Bone Diseases, Metabolic
Bone Diseases
 Musculoskeletal Diseases
Calcium Metabolism Disorders
Metabolic Diseases
Vitamin D Deficiency
Deficiency Diseases
Malnutrition
Ergocalciferols
Vitamin D
Vitamins
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on May 19, 2013